Bevacizumab Benefit Varies Among Ovarian Cancer Subtypes

Jason Harris
Published Online: Friday, May 19, 2017

Brian Slomovitz, MD

Brian Slomovitz, MD

Patients with proliferative or mesenchymal ovarian tumors treated with bevacizumab (Avastin) had superior progression-free survival (PFS) and a trend toward improved overall survival (OS) compared with patients with immunoreactive or differentiated tumors, according to results published in Clinical Cancer Research.

In univariate analysis, adding bevacizumab to standard chemotherapy with carboplatin and paclitaxel was associated with a median PFS of 21.9 months versus 11.8 months for standard chemotherapy alone in patients with the proliferative subtype of ovarian tumors. That represents an improvement of 10.1 months (HR, 0.55; 95% CI, 0.34-0.90; P = .016).

Bevacizumab was associated with a nonsignificant improvement in PFS of 8.2 months (HR, 0.78; 95% CI, 0.44-1.40; P = .41) in patients with mesenchymal subtype tumors.

“We demonstrate that molecular subtypes with the poorest survival (proliferative and mesenchymal) derive a comparably greater benefit from treatment which includes bevacizumab,” the researchers wrote. “Taken together, these data indicate that stratifying patients by molecular subtype could be an effective therapeutic strategy for ovarian cancer.”

In the paper, Stefan Kommoss, MD, with the department of women’s health at Tuebingen University Hospital in Tuebingen, Germany, and his colleagues noted that antiangiogenic treatment is crucial to treating in ovarian cancer, but there is no biomarker identifying which patients are most likely to benefit. They designed this study to determine whether there was a correlation between ovarian cancer molecular subtypes and outcomes after treatment with bevacizumab.

Researchers reviewed gene expression array data from patients enrolled in the AGO-OVAR11 trial, the German cohort from the ICON7 multicenter phase III trial. In that trial, women with peritoneal, tubal, or ovarian carcinoma were randomly assigned to carboplatin and paclitaxel with or without bevacizumab.

Of the 359 patients included in this analysis, 73 (20%) had differentiated tumors, 122 (34%) tumors were immunoreactive, 68 (19%) were mesenchymal, and 96 were proliferative (27%). Patients were separated into bevacizumab (n = 189) and standard chemotherapy alone (n = 170) cohorts.

For all patients, there was a 6.5-month improvement in median PFS for the bevacizumab arm compared with the standard arm (21.1 vs 14.6; HR, 0.68; 95% CI, 0.53-0.89; P = .005). When adjusted for high risk of progression, age, grade, and histology, Cox regression analysis showed that bevacizumab significantly improved PFS (HR, 0.64; 95% CI, 0.49-0.83; P = .0008). Improvement in OS was only borderline significant (HR, 0.66; 95% CI, 0.44-1.00; P = .05).

In univariate analysis of the immunoreactive and differentiated subtypes, bevacizumab produced nonsignificant PFS improvements of 3.8 months (P = .08) and 3.7 months (P = .61), respectively. Improvements in PFS for the mesenchymal, immunoreactive, and differentiated groups remained nonsignificant in multivariate analysis.

In preliminary OS results, only the proliferative subtype showed a statistically significant trend toward improved OS (HR, 0.50; 95% CI, 0.24-1.03; P = .06). Multivariate analysis showed that any improvements in OS in the mesenchymal, immunoreactive, and differentiated groups were nonsignificant.

“The present investigation is the first to examine the correlation of ovarian cancer molecular subtypes with outcome after treatment with bevacizumab in a randomized controlled phase III trial of primary ovarian cancer,” wrote Kommoss et al. “We show that the proliferative and mesenchymal molecular subtypes appear to benefit most, with a prolongation in PFS and a trend toward greater OS.”

Brian Slomovitz, MD, director of the division of gynecologic oncology at the University of Miami Sylvester Comprehensive Cancer Center, reviewed the results for OncLive. While he said the findings had “great promise,” it’s impossible to draw any conclusions until the results are validated in a prospective study.

“This study reflects great potential,” he said. “Why do we want to identify patients who respond to different therapies? One, so patients can be directed toward that therapy. But perhaps more importantly, to prevent a patient from receiving a noneffective therapy, one in which they’d only be receiving side effects without the potential benefit.

“It’s an interesting idea. It’s a great idea. In order for us to get better at treating patients with cancer, we need to do a better job identifying different subgroups of patients who will respond to different therapies.”
Kommoss S, Winterhoff B, Oberg AL, et al. Bevacizumab may differentially improve ovarian cancer outcome in patients with proliferative and mesenchymal molecular subtypes. Clin Cancer Res [published online February 3, 2017]. doi:10.1158/1078-0432.CCR-16-2196.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Expert Perspectives in PARP Inhibition: Evolving Management Strategies in Ovarian CancerJun 24, 20172.0
Medical Crossfire<sup>®</sup>: The Expanding Role of PARP Inhibitors in the Treatment of Ovarian Cancers – Current Strategies and Future DirectionJan 30, 20181.5
Publication Bottom Border
Border Publication